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Risk of mature B-cell neoplasms and precursor conditions after
joint replacement: A report from the Haematological
Malignancy Research Network
Eleanor Kane 1, Daniel Painter1, Alexandra Smith1, Maxine Lamb1, Steven E. Oliver1,2, Russell Patmore3 and
Eve Roman 1
1Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, United Kingdom
2Hull York Medical School, York, United Kingdom
3Queens Centre for Oncology, Castle Hill Hospital, Hull, United Kingdom
Associations between previous joint replacement and B-cell lymphoid malignancies have been reported, but despite numerous
reports, associations with the disease subtypes have received little attention. Using a UK-based register of haematological
malignancies and a matched general population-based cohort, joint replacements from linked hospital inpatient records were
examined. Cases diagnosed 2009–2015 who were aged 50 years or more were included; 8,013 mature B-cell neoplasms
comprising myeloma (n = 1,763), diffuse large B-cell lymphoma (DLBCL, n = 1,676), chronic lymphocytic leukaemia
(CLL, n = 1,594), marginal zone lymphoma (MZL, n = 957), follicular lymphoma (FL, n = 725) and classical Hodgkin lymphoma
(CHL, n = 255), together with monoclonal gammopathy of uncertain significance (MGUS, n = 2,138) and monoclonal B-cell
lymphocytosis (MBL, n = 632). Odds ratios (OR) and 95% confidence intervals (95%CI) were calculated relative to 10 age- and
sex-matched controls using conditional logistic regression. Having had a joint replacement before diagnosis was associated
with myeloma (OR = 1.3, 95% CI 1.1–1.5, p = 0.008) and MGUS (OR = 1.3, 95% CI 1.1–1.5, p < 0.001). Excluding replacements
in the year before diagnosis, the MGUS risk remained, elevated where two or more joints were replaced (OR = 1.5, 95% CI
1.2–2.0, p = 0.001), with hip (OR = 1.2, 95% CI 1.0–1.5, p = 0.06) or knee replacements (OR = 1.5, 95% CI 1.2–1.8,
p < 0.001). Associations with CHL and two or more replacements (OR = 2.7, 95% CI 1.3–5.6, p = 0.005) or hip replacements
(OR = 1.9, 95% CI 1.0–3.4, p = 0.04); and between DLBCL and knee replacements (OR = 1.3, 95% CI 1.0–1.6, p = 0.04) were
also observed. Our study reports for the first time a relationship between joint replacements and MGUS; while absolute risks
of disease are low and not of major public health concern, these findings warrant further investigation.
Introduction
Including chronic lymphocytic leukaemia (CLL), myeloma
and more than 90% of lymphomas, mature B-cell malignancies
account for around 60% of all haematological cancers.1,2 With
diverse epidemiological features, treatment pathways, and
outcomes these cancers comprise a heterogeneous group of
over 50 subtypes.1 For some subtypes, environmental risk fac-
tors are well established; including biological (e.g. certain
infections), physical (e.g. ionising radiation) and chemical
(e.g. pesticides) agents.3–7 A number of familial predisposition
syndromes and genetic risk factors have also been implicated,
as have several acquired comorbidities (e.g. autoimmunity)
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and drugs/procedures associated with immunosuppression
(e.g. organ transplantation).8–13 Currently, however, known
risk factors only account for a relatively small proportion of
the total mature B-cell cancer burden.
With a view to gaining additional insight into the pathogene-
sis of mature B-cell malignancies, epidemiological research is
increasingly focusing on the molecular aspects of these complex
malignancies, as well as exposures and conditions that interact
with the immune system.14–19 In this regard, precursor lympho-
proliferative conditions, which have been shown to share some
of the same risk factors as their malignant counterparts, are also
of interest; the two most notable being monoclonal gammopathy
of undetermined significance (MGUS) and monoclonal B-cell
lymphocytosis (MBL).20–22 Both of these asymptomatic clonal
disorders are associated with subsequent progression to mature
B-cell malignancies: non-IgM and light-chain MGUS to mye-
loma (at a rate of around 1% per year) and the less common
IgM MGUS to other lymphoproliferative neoplasms (at rate of
about 1.5% per year)1,21,23; the high-count MBL CLL-type, which
accounts for around 75% of the total, progressing to CLL at a
rate of around 1–2% a year.1,22,24
The present report concerns the potential impact that pre-
vious joint replacements may have on the subsequent develop-
ment of mature B-cell malignancies and their precursor
conditions. Many materials used in orthopaedic implants are
suspected carcinogens,25 and replacements can produce debris
and also inflammation.26,27 Accordingly, with the aim of inves-
tigating the potential adverse health effects of such procedures,
several cohorts of joint replacement recipients have been
established; and although findings for all cancers combined
have tended to be equivocal, those for mature B-cell malignan-
cies are more consistent, albeit often based on comparatively
small numbers of events.28–38Using a more statistically power-
ful design, this article presents findings from a case–control
study embedded within a population-based cohort of patients
with haematological malignancies (cases) and a matched
cohort of unaffected individuals from the general population
(controls).
Methods
Cases were from the UK Haematological Malignancy Research
Network (HMRN, www.hmrn.org), a specialist register initi-
ated in September 2004 which provides real-world data on all
haematological cancers and precursor conditions that can be
generalised to the UK as a whole.39 HMRN collects all diagno-
ses, including progressions and transformations, reported and
coded to the latest WHO ICD-O31 by clinical specialists.40 Set in
a catchment population of 4 million people served by 14 hospitals,
the network registers ~2,400 haematological malignancy diag-
nosed each year. In order to facilitate comparisons with the gen-
eral population, HMRN also has a general-population cohort;
patients diagnosed between January 1, 2009 and December
31, 2015 were each matched on age and sex to 10 unaffected indi-
viduals from the same catchment population.11 HMRN operates
under a legal basis that permits full treatment and outcome data
to be collected from clinical records without explicit consent, and
all cases and controls are linked to nationwide information on
deaths, cancer registrations and Hospital Episode Statistics (HES).
This report includes 10,783 patients aged 50 years or over newly
diagnosed with a mature B-cell malignancy or precursor condi-
tion between 1 January 2009 and 31 December 2015 and their
age- and sex-matched controls (n = 107,830). The malignancies
included were myeloma (n = 1,763), DLBCL (n = 1,676), CLL
(n = 1,594), MZL (n = 957), FL (n = 725) and CHL (n = 255);
and the precursor conditions were MGUS (n = 2,138) and MBL
(n = 632); and all controls were assigned a “pseudodiagnosis date”
equivalent to the date of diagnosis of their matched case.
Joint replacements are among the most common surgical oper-
ations conducted in patients over 40 years.41 In England, around
two-thirds of joint replacements are funded by the NHS,42 which
are recorded with the date of the operation in HES Admitted
Patient Care (HES-APC), regardless of whether they are performed
by the NHS or the independent sector. For the present analysis, all
joint replacement operations performed between April 1, 1997 and
before the date of diagnosis (patient cohort members), or the
corresponding pseudodiagnosis date (comparator cohort mem-
bers) were extracted using OPCS4 codes (OPCS Classification of
Interventions and Procedures Version 4 codes43) relating to joint
replacement operations (Table 1). Focus was on the commonest
prosthetics (hip, knee, shoulder, elbow or ankle); with data on pri-
mary replacements, resurfacing procedures, revisions, conversions
and any other related operation included. Laterality of each proce-
dure was also extracted, with coincident bilateral operations being
counted twice, once for each side. As well as examining joint
replacements up to diagnosis/pseudodiagnosis, analyses were
repeated excluding any joint replacements that occurred in the year
What’s new?
While lymphoid malignancies are increased in persons with previous joint replacements, data on associations with particular
diagnostic subtypes is lacking. Here, the authors investigated the relationship between joint replacement and mature B-cell
neoplasms and their precursor conditions in an established cohort of patients with hematological malignancies linked to
national healthcare records. Previous joint replacement was associated with subsequent elevated risk of myeloma, monoclonal
gammopathy of uncertain significance, and Hodgkin lymphoma subtypes of hematological disease. While the findings indicate
that absolute risks are low, joint replacement procedures are increasing and disentangling the underlying reasons behind
these associations warrants further investigation.
2 B-cell neoplasm risk after joint replacement
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or 5 years before diagnosis/pseudodiagnosis. To quantify associa-
tions between joint replacements and malignancy, odds ratios
(ORs) and 95% confidence intervals (CIs) were estimated using
conditional logistic regression. Since cohort members could have
replacements in different types of joints, risk estimates for specific
joints were adjusted for whether or not they had had replacements
in other joints. All analyses were conducted using Stata 15.1.44
Ethics approval
HMRN has ethical approval from Leeds (West) Research Ethics
Committee (reference 04/Q1205/69) and the Health Research
Authority Confidentiality Advisory Group under Section 251 of
the NHS Act (2006; reference PIAG 1-05 (h)/2007).
Data availability
The data that support the findings of our study are available
from the corresponding author upon reasonable request.
Results
Joint replacements occurred in 995/10783 (9.2%) cases and
9179/107830 (8.5%) controls prior to the date of diagnosis/pseu-
dodiagnosis. Osteoarthritis was the most frequent indication for
the first replacement (75.5% among cases, 76.7% among controls),
Table 1. OPCS4 Codes for operations involving a joint replacement in the hip, knee, shoulder, elbow or ankle
OPCS4 Codes
Joint Joint-specific replacement operations Replacement operations where joint identified separately (+ Z codes)
(W05, W43–W45, W55, W58, W91.3, W91.8)
Hip W37–W39, W46–W48, W93–W95 + (Z75.6, Z76.1–Z76.2, Z76.8–Z76.9, Z84.3, Z84.9)
Knee W40–W42, O18 + (Z76.5, Z77.3–Z77.5, Z77.8–Z77.9, Z78.7, Z84.4–Z84.6)
Shoulder W49–W51, W96–W98, O06–O08 + (Z69.1, Z81.2–Z81.4)
Elbow W52–W54, O21–O26 + (Z70.1, Z81.5)
Ankle O32 + (Z85.6, Z85.8)
Operations were recorded using OPCS4 versions 4.2–4.7. Codes for primary joint replacements end with 0.1, 0.8 or 0.9 except in the shoulder, where
the codes W50.4, W51.5, W96.5 and W98.6 also define primary replacements/resurfacing. Laterality was identified using the codes Z94.1, Z94.2, Z94.3
for bilateral; right- and left-sided operations, respectively.
Table 2. Risk of mature B-cell neoplasms and precursor conditions after a joint replacement in the hip, knee, ankle, shoulder or elbow up to
diagnosis/pseudodiagnosis date or up to 1 or 5 years before diagnosis/pseudodiagnosis date
Up to diagnosis Up to 1 year before diagnosis Up to 5 years before diagnosis
Cases
n
%
Cases
%
Controls
OR
(95% CI)
%
Cases
%
Controls
OR
(95% CI)
%
Cases
%
Controls
OR
(95% CI)
Mature B-cell
neoplasms
Total 8,013 8.7 8.4 1.0 (1.0–1.1) 7.7 7.5 1.0 (0.9–1.1) 4.8 4.5 1.1 (1.0–1.2)
Myeloma 1,763 10.2 8.3 1.3 (1.1–1.5) 8.6 7.5 1.2 (1.0–1.4) 5.0 4.5 1.1 (0.9–1.4)
Diffuse large B-cell
lymphoma
1,676 9.4 9.1 1.0 (0.9–1.2) 8.5 8.0 1.1 (0.9–1.3) 5.4 4.7 1.2 (0.9–1.5)
Chronic lymphocytic
leukaemia
1,594 7.0 8.1 0.8 (0.7–1.0) 6.3 7.3 0.9 (0.7–1.1) 4.1 4.4 0.9 (0.7–1.2)
Marginal zone
lymphoma
957 9.5 8.6 1.1 (0.9–1.4) 8.5 7.7 1.1 (0.9–1.4) 4.8 4.8 1.0 (0.7–1.4)
Follicular lymphoma 725 7.2 7.6 0.9 (0.7–1.3) 6.3 6.7 0.9 (0.7–1.3) 3.2 3.9 0.8 (0.5–1.2)
Classical Hodgkin
lymphoma
255 9.0 6.5 1.4 (0.9–2.3) 7.8 5.9 1.4 (0.8–2.3) 6.7 3.5 2.0 (1.2–3.5)
Precursor conditions
Monoclonal
gammopathy of
undetermined
significance
2,138 11.4 9.1 1.3 (1.1–1.5) 10.2 8.1 1.3 (1.1–1.5) 7.0 4.9 1.5 (1.2–1.8)
Monoclonal B-cell
lymphocytosis
632 8.4 8.1 1.0 (0.8–1.4) 7.9 7.3 1.1 (0.8–1.5) 5.1 4.3 1.2 (0.8–1.7)
Odds ratios (OR) and 95% confidence intervals (95% CI) comparing HMRN cases aged 50 or over and diagnosed 2009–2015 to 10 individually age-sex
matched controls were estimated using conditional logistic regression.
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with fractures accounting for a further 11.3% in both cases and
controls. Although no association with joint replacement was
observed for all mature B-cell neoplasms combined (OR = 1.0,
95%CI 1.0–1.1, p = 0.33), the risk varied by subtype, being highest
for myeloma (OR = 1.3, 95%CI 1.1–1.5, p = 0.008) and CHL
(OR = 1.4, 95%CI 0.9–2.3, p = 0.13), but below or close to unity
Myeloma Diffuse large B-cell lymphoma Chronic lymphocytic leukaemia
Controls (%) Controls (%) Controls (%)Cases(%) Cases (%) Cases (%)Odds Ratio (95%) Confidence Interval) Odds Ratio (95% Confidence Interval) Odds Ratio (95%) Confidence Interval)
(n = 17630) (n = 16760) (n = 15940)(n = 1763) (n = 1676) (n = 1594)
Number of Joint Replacements
Years before diagnosis of first joint replacement
Joint(s) replaced
Any
Two or more
1−<5
5+
Hip
Knee
7.5
1.9
3.0
4.5
3.9
3.6
8.0
2.1
3.3
4.7
4.4
3.6
7.3
1.9
2.8
4.4
4.0
3.4
8.6
2.7
3.5
5.0
4.8
4.1
8.5
2.5
3.0
5.4
4.2
4.7
6.3
1.6
2.3
4.1
2.9
3.3
1.2(1.0−1.4)
1.4(1.0−1.9)
1.2(0.9−1.6)
1.1(0.9−1.4)
1.2(1.0−1.6)
1.2(0.9−1.5)
1.1(0.9−1.3)
1.2(0.9−1.7)
0.9(0.7−1.2)
1.2(0.9−1.5)
1.0(0.7−1.2)
1.3(1.0−1.6)
0.9(0.7−1.1)
0.8(0.5−1.2)
0.8(0.6−1.1)
0.9(0.7−1.2)
0.7(0.5−1.0)
0.9(0.7−1.3)
Marginal zone lymphoma Follicular lymphoma Classical Hodgkin lymphoma
Controls (%) Controls (%) Controls (%)Cases (%) Cases (%) Cases (%)Odds Ratio (95% Confidence Interval) Odds Ratio (95% Confidence Interval) Odds Ratio (95% Confidence Interval)
(n = 9570) (n = 7250) (n = 2550)(n = 957) (n = 725) (n = 255)
Years before diagnosis of first joint replacement
Number of Joint Replacements
Joint(s) replaced
Any
Two or more
1−<5
5+
Hip
Knee
7.7
2.1
2.9
4.8
4.0
3.8
6.7
1.8
2.8
3.9
3.5
3.2
5.9
1.5
2.4
3.5
3.0
2.8
8.5
2.0
3.7
4.8
4.2
3.9
6.3
2.2
3.2
3.2
3.2
3.2
7.8
3.9
1.2
6.7
5.5
2.7
1.1(0.9−1.4)
1.0(0.6−1.5)
1.3(0.9−1.8)
1.0(0.7−1.4)
1.0(0.7−1.5)
1.0(0.7−1.5)
0.9(0.7−1.3)
1.2(0.7−2.1)
1.1(0.7−1.8)
0.8(0.5−1.2)
0.9(0.6−1.4)
1.0(0.6−1.5)
1.4(0.8−2.3)
2.7(1.3−5.6)
0.5(0.2−1.6)
2.0(1.2−3.4)
1.9(1.0−3.4)
1.0(0.5−2.3)
0.5 1 2 3
Monoclonal gammopathy of undetermined significance Monoclonal B−cell lymphocytosis
Controls (%) Controls (%)Cases (%) Cases (%)Odds Ratio (95%) Confidence Interval) Odds Ratio (95% Confidence Interval)
(n = 21380) (n = 6320)(n = 2138) (n = 632)
Number of Joint Replacements
Years before diagnosis of first joint replacement
Joint(s) replaced
Any
Two or more
1−<5
5+
Hip
Knee
8.1
2.3
3.2
4.9
4.3
4.1
7.3
1.6
3.0
4.3
3.9
3.4
10.2
3.3
3.2
7.0
5.1
5.8
7.9
2.2
2.8
5.1
4.6
3.6
1.3(1.1−1.5)
1.5(1.2−2.0)
1.0(0.8−1.3)
1.5(1.2−1.8)
1.2(1.0−1.5)
1.5(1.2−1.8)
1.1(0.8−1.5)
1.4(0.8−2.4)
1.0(0.6−1.6)
1.2(0.8−1.7)
1.2(0.8−1.8)
1.1(0.7−1.7)
0.5 1 2 3 0.5 1 2 3
Figure 1. Mature B-cell neoplasms and precursor conditions diagnosed 2009–2015 aged 50 or over and their age-sex matched controls with one
or more operations involving a joint prosthesis in the hip, knee, ankle, shoulder or elbow up to 1 year before diagnosis/pseudodiagnosis, odds
ratios (OR) and 95% confidence intervals (CI), distributed by number of joints replaced, number of years between first joint replacement and
diagnosis/pseudodiagnosis and specific joint(s) replaced. Boxes are weighted to the total number of cases and controls. [Color figure can be
viewed at wileyonlinelibrary.com]
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for DLBCL, MZL, FL and CLL (Table 2). An increased risk was
also seen for MGUS (OR = 1.3, 95%CI 1.1–1.5, p < 0.001), but
not for MBL. The associations with MGUS and CHL remained
when operations performed in the 1 or 5 years before diagnosis
were removed, but did not for myeloma (Table 2).
In the time window up to a year before diagnosis, 8.2% of
cases and 7.6% of controls had at least one joint replaced, and
among those with replacements, over a quarter had two or more
separate joints replaced (29.2% of cases and 26.6% of controls
with a replacement). As shown in Figure 1, risks were raised when
two or more joints were replaced for myeloma (OR = 1.4, 95% CI
1.0–1.9, p = 0.03), MGUS (OR = 1.5, 95% CI 1.2–2.0, p = 0.001)
and CHL (OR = 2.7, 95% CI 1.3–5.6, p = 0.005). For MGUS and
CHL, the effect was also found 5 or more years before diagnosis
(MGUS: OR = 1.5, 95% CI 1.2–1.8, p < 0.001; CHL: OR = 2.0,
95% CI 1.2–3.4, p = 0.01). The pattern for myeloma was less clear,
as risk estimates were similar for 1 to <5 years and 5 or more
years before diagnosis (OR = 1.2, 95% CI 0.9–1.6, p = 0.17;
OR = 1.1, 95% CI 0.9–1.4, p = 0.27, respectively).
As expected most operations were on hip or knee joints, and,
in almost equal numbers; less than 5% were performed on the
shoulder, elbow or ankle joints. MGUS and myeloma risks were
raised after both hip and knee replacements (MGUS: OR = 1.2,
95% CI 1.0–1.5, p = 0.06 and OR = 1.5, 95% CI 1.2–1.8,
p < 0.001; myeloma: OR = 1.2, 95% CI 1.0–1.6, p = 0.08 and
OR = 1.2, 95% CI 0.9–1.5, p = 0.24 for hip and knee, respectively).
For CHL, the risk was increased with hip (OR = 1.9, 95% CI
1.0–3.4, p = 0.04) rather than knee replacements (OR = 1.0, 95%
CI 0.5–2.3, p = 0.96; Fig. 1). Among other subtypes, associations
were generally lacking, exceptions being an increased risk of
DLBCL after knee replacement (OR = 1.3, 95%CI 1.0–1.6,
p = 0.04) and of MZL with shoulder replacement (OR = 2.6, 95%
CI 1.2–5.6, p = 0.02). Although those who had a joint replacement
tended to be older at diagnosis/pseudodiagnosis than those who
had not (mean age 77.2, 95% CI 76.7–77.8 compared to 71.6, 95%
CI 71.4–71.8), risks did not vary by age, or by sex either (data not
shown).
Findings for MGUS among those with IgM (n = 342) and
non-IgM (n = 1,655) subtypes are shown in Table 3. For IgM
MGUS, the risk estimate with any joint replacement was slightly
higher (OR = 1.7, 95% CI 1.2–2.4), but not significantly different
from that for non-IgM MGUS (OR = 1.3, 95% CI 1.1–1.5). Simi-
larly, we found little difference between the two MGUS subtypes
when the number of primary joint replacements, the time before
the diagnosis of the first replacement, and whether hip or knee
joints were replaced were examined.
Discussion
This is the first study to describe associations between previous
joint replacements across the spectrum of mature B-cell malignan-
cies and precursor conditions. Using a population-based case–
control design, this large record linkage study with over 8,000 cases
with mature B-cell neoplasms, 2,700 with precursor conditions
and 10 times as many controls found associations between jointTa
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replacements and subsequent MGUS, myeloma and CHL. We
found that the risk of both MGUS and CHL were increased with
joint replacements several years before diagnosis, while that for
myeloma was present with replacements in the year before diagno-
sis and less so with replacements at earlier times; this latter observa-
tion leaving open the possibility that some procedures may have
been carried out on patients whose myeloma had not yet been
detected. In all cases, the associations increased with increasing
numbers of replacements; MGUS and myeloma were associated
with both hip and knee, whereas CHL was primarily linked with
hip. Neither DLBCL nor MZL were associated with joint replace-
ments overall, although increased risks were observed for knee and
shoulder replacements, respectively. Consistent with the heteroge-
neity of B-cell neoplasms, we found no associations for the other
most common subtypes.
In contrast to most population-based registers, HMRN
has world-class centralised diagnostics, following strict
condition-specific criteria for accuracy and consistency
across the spectrum of haematological malignancies; MGUS,
for example, is diagnosed with the presence of neoplastic
plasma cells in the bone marrow in addition to detectable
paraprotein in peripheral blood. Our study was also specifi-
cally designed to make robust comparisons between patients
with haematological malignancies and the general popula-
tion; HMRN’s controls comprise age- and sex-matched indi-
viduals randomly sampled from the study’s catchment
population, and both HMRN’s cases and controls are linked
to the same nationwide administrative databases. This case–
control approach, novel among the studies of joint replace-
ment recipients,28–38 yielded large numbers of cases in well-
defined diagnostic categories. With healthcare data available
from April 1, 1997, our study captured primary replacements
for any major joint through to the date of diagnosis/pseudo-
diagnosis (January 1, 2009, to December 31, 2015), and so
unlike others, was able to examine associations with the
number, as well as specific joints replaced, as well as the time
since the first replacement.
Prior studies have followed joint replacement recipients from
their first hip or knee replacement for average periods of around
4–8 years postoperation.28–38 In agreement with national data
on joint replacements,45 we found that the median age at the
first joint replacement was around 70 years of age; no differ-
ences of note were detected between cases and controls, or by
disease subtype. Seventy years of age is also around the median
age at which B-cell neoplasms are diagnosed, apart from CHL
where the median age at diagnosis is 41.2 We did not find asso-
ciations in the year leading up to diagnosis, with the exception
of myeloma; increased risks were instead found where the first
joint was replaced five or more years before the diagnosis. Con-
sequently, joint replacement recipients tended to be diagnosed
with a B-cell condition at later ages (mean age of 77.2); with our
analysis restricted to persons aged 50 or over, the comparison
for CHL was a mean age of 76.5 among recipients compared to
67.2 overall. In the absence of associations closer to diagnosis
(1 to <5 years), these observations are consistent with a longer
latency between joint replacement and the diagnosis of a B-cell
condition.
While our study has many strengths, weaknesses may have
arisen through the use of HES data to define our exposure. In
England, hospital data are available back to the year 1997 and
for our cohorts, this timeframe covered more than a decade of
secondary healthcare records before diagnosis/pseudodiagnosis
(2009–2015). We believe this is sufficient coverage to identify
the majority of individuals aged 50 or over who had previous
major prosthetic work recorded in HES. HES records operations
funded by the NHS in England, so joint replacement operations
performed outside England or funded privately cannot be
accounted for. Although the impact of the former may be mini-
mal, privately funded replacements comprise a reasonable pro-
portion of all major joint replacement operations, currently
around a third of the total.42 However, since case and control
distributions of socioeconomic status at the time of the first joint
replacement were similar, and in contrast to some other cancers,
haematological malignancies are not related to socioeconomic
status,2 cases having joint replacements conducted outside the
NHS more (or less) often than controls seems unlikely. A criti-
cism common to previous studies is the healthy recipient effect,
whereby persons undergoing major surgery to replace a joint are
healthier than the general population, introducing bias in pro-
spective cohorts at the point of ascertainment. Here, individuals
were ascertained at the time of haematological malignancy
diagnosis/pseudodiagnosis typically several years postimplant,
minimising any healthy recipient effect except perhaps in the
year prior, where no decreased risks were found. Our reliance
on OPCS clinical codes for joint replacements meant that the
type of prosthetic could not be specified; metal-on-metal pros-
thetics (MoM) are one type to have received attention, but
where MoM recipients were compared to those who received
other types, the risk of lymphoproliferative cancer was found to
be no different.46–49
In this first study to examine whether joint replacements
are related to mature B-cell neoplasms and precursor condi-
tions, we found the most consistent associations for myeloma,
MGUS and CHL. Across these three subtypes, associations
were, on the whole, present after joint replacements several
years before diagnosis; with multiple primary replacements;
and with replacements in the hip and knee joints. Contrary to
these observations, we found little or no evidence that joint
replacements were associated with the other subtypes, namely
DLBCL, MZL, CLL, FL and MBL. Conducted in a period
when the number of joint replacements performed is
increasing,50 our findings must be considered in the context
of low absolute risk of any of these diagnosis and should not
raise major public health concerns; nevertheless, whether the
prosthetics or the underlying reasons for the procedures are
the likely explanation warrants further investigation.
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